November 3, 2006. The National Research Center for Women & Families strongly supports the WIC Food Packages Proposed Rule. A healthful diet is a family responsibility, but WIC policies are essential in encouraging the best possible nutrition for low-income families, and a healthy start for young children.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Report to FDA Advisory Committees: Does Approval Mean Safety?
September 17, 2006. The U.S. Food and Drug Administration (FDA) has the responsibility to determine if newly developed medical products are safe and effective.
Read More »Letter to the Senate HELP Committee on Enhancing Drug Safety and Innovation Act
September 28, 2006. NCHR was disappointed to hear that the Senate is considering marking up S. 3807 “The Enhancing Drug Safety and Innovation Act” before holding a hearing.
Read More »Invited Testimony Before the Standing Committee on Health, Canadian Parliament, Ottawa
June 8, 2006. Clinical trials are a major source of information on the short-term risks of silicone breast implants. In clinical trials, the goal is to follow women prospectively to determine what complications and health problems occur, and to compare that to a control group.
Read More »NCHR Statement on FDA ‘Approvable’ Letter for Breast Implant Manufacturer
September 24, 2005. The Food and Drug Administration (FDA) issued an “approvable letter” to Inamed Corporation for their silicone gel breast implants, and NCHR finds this unacceptable.
Read More »